Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.
Zanetti SR, Velasco-Hernandez T, Gutierrez-Agüera F, Díaz VM, Romecín PA, Roca-Ho H, Sánchez-Martínez D, Tirado N, Baroni ML, Petazzi P, Torres-Ruiz R, Molina O, Bataller A, Fuster JL, Ballerini P, Juan M, Jeremias I, Bueno C, Menéndez P. Zanetti SR, et al. Among authors: jeremias i. Mol Ther. 2022 Feb 2;30(2):550-563. doi: 10.1016/j.ymthe.2021.08.033. Epub 2021 Sep 1. Mol Ther. 2022. PMID: 34478871 Free PMC article.
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
Baroni ML, Sanchez Martinez D, Gutierrez Aguera F, Roca Ho H, Castella M, Zanetti SR, Velasco Hernandez T, Diaz de la Guardia R, Castaño J, Anguita E, Vives S, Nomdedeu J, Lapillone H, Bras AE, van der Velden VHJ, Junca J, Marin P, Bataller A, Esteve J, Vick B, Jeremias I, Lopez A, Sorigue M, Bueno C, Menendez P. Baroni ML, et al. Among authors: jeremias i. J Immunother Cancer. 2020 Jun;8(1):e000845. doi: 10.1136/jitc-2020-000845. J Immunother Cancer. 2020. PMID: 32527933 Free PMC article.
Enforced sialyl-Lewis-X (sLeX) display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activity and bone marrow homing.
Sánchez-Martínez D, Gutiérrez-Agüera F, Romecin P, Vinyoles M, Palomo M, Tirado N, Zanetti SR, Juan M, Carlet M, Jeremias I, Menéndez P. Sánchez-Martínez D, et al. Among authors: jeremias i. Clin Transl Med. 2021 Feb;11(2):e280. doi: 10.1002/ctm2.280. Clin Transl Med. 2021. PMID: 33634970 Free PMC article.
The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia.
Lopez-Millan B, Costales P, Gutiérrez-Agüera F, Díaz de la Guardia R, Roca-Ho H, Vinyoles M, Rubio-Gayarre A, Safi R, Castaño J, Romecín PA, Ramírez-Orellana M, Anguita E, Jeremias I, Zamora L, Rodríguez-Manzaneque JC, Bueno C, Morís F, Menendez P. Lopez-Millan B, et al. Among authors: jeremias i. Cancers (Basel). 2022 Mar 21;14(6):1593. doi: 10.3390/cancers14061593. Cancers (Basel). 2022. PMID: 35326743 Free PMC article.
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, Scheurer M, Muth A, Hänel G, Nixdorf D, Sponheimer M, Ohlmeyer M, Lacher SM, Brauchle B, Marcinek A, Rohrbacher L, Leutbecher A, Rejeski K, Weigert O, von Bergwelt-Baildon M, Theurich S, Kischel R, Jeremias I, Bücklein V, Subklewe M. Philipp N, et al. Among authors: jeremias i. Blood. 2022 Sep 8;140(10):1104-1118. doi: 10.1182/blood.2022015956. Blood. 2022. PMID: 35878001 Free PMC article.
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M. Krupka C, et al. Among authors: jeremias i. Leukemia. 2016 Feb;30(2):484-91. doi: 10.1038/leu.2015.214. Epub 2015 Aug 4. Leukemia. 2016. PMID: 26239198
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Augsberger C, Hänel G, Xu W, Pulko V, Hanisch LJ, Augustin A, Challier J, Hunt K, Vick B, Rovatti PE, Krupka C, Rothe M, Schönle A, Sam J, Lezan E, Ducret A, Ortiz-Franyuti D, Walz AC, Benz J, Bujotzek A, Lichtenegger FS, Gassner C, Carpy A, Lyamichev V, Patel J, Konstandin N, Tunger A, Schmitz M, von Bergwelt-Baildon M, Spiekermann K, Vago L, Jeremias I, Marrer-Berger E, Umaña P, Klein C, Subklewe M. Augsberger C, et al. Among authors: jeremias i. Blood. 2021 Dec 23;138(25):2655-2669. doi: 10.1182/blood.2020010477. Blood. 2021. PMID: 34280257 Free PMC article.
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance.
Wirth AK, Wange L, Vosberg S, Henrich KO, Rausch C, Özdemir E, Zeller CM, Richter D, Feuchtinger T, Kaller M, Hermeking H, Greif PA, Senft D, Jurinovic V, Bahrami E, Jayavelu AK, Westermann F, Mann M, Enard W, Herold T, Jeremias I. Wirth AK, et al. Among authors: jeremias i. Leukemia. 2022 Dec;36(12):2863-2874. doi: 10.1038/s41375-022-01726-7. Epub 2022 Nov 4. Leukemia. 2022. PMID: 36333584 Free PMC article.
145 results